SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue for the March 2022 quarter is pegged at Rs. 12550.20 millions, about 14.56% up against Rs. 10955.40 millions recorded during the year-ago period.A comparatively good net profit growth of 38.66% to Rs. 2114.10 millions was reported for the quarter ended March 2022 compared to Rs. 1524.70 millions of previous same quarter.The company reported a good operating profit of 3148.70 millions compared to 2217.30 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 12550.20 10955.40 14.56 49192.70 43100.20 14.14 49192.70 43100.20 14.14
Other Income 210.50 162.00 29.94 772.10 809.00 -4.56 772.10 809.00 -4.56
PBIDT 3148.70 2217.30 42.01 11649.30 10023.60 16.22 11649.30 10023.60 16.22
Interest 51.40 47.40 8.44 191.00 182.80 4.49 191.00 182.80 4.49
PBDT 3097.30 2169.90 42.74 11458.30 9840.80 16.44 11458.30 9840.80 16.44
Depreciation 174.30 151.10 15.35 661.00 581.30 13.71 661.00 581.30 13.71
PBT 2923.00 2018.80 44.79 10797.30 9259.50 16.61 10797.30 9259.50 16.61
TAX 808.90 494.10 63.71 2810.30 2352.60 19.46 2810.30 2352.60 19.46
Deferred Tax 74.20 10.70 593.46 41.80 -37.90 -210.29 41.80 -37.90 -210.29
PAT 2114.10 1524.70 38.66 7987.00 6906.90 15.64 7987.00 6906.90 15.64
Equity 212.50 212.50 0.00 212.50 212.50 0.00 212.50 212.50 0.00
PBIDTM(%) 25.09 20.24 23.96 23.68 23.26 1.82 23.68 23.26 1.82

Abbott India Share Price

25797.15 -65.00 (-0.25%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×